Rates of progression-free survival by molecular responses at 1 and 3 months.31
The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia, Vol. 120, No. 6, 2003, 990–999. © 2003 British Journal of Hematology; Reprinted with permission of Wiley-Blackwell, Inc.